Skip to main content

Table 6 Summary results of the cost-effectiveness analysis

From: Estimation of the cost-effectiveness of apixaban versus vitamin K antagonists in the management of atrial fibrillation in Argentina

 

VKA Suitable Patients

 

Apixaban-Warfarin

Net Cost

USD 135,06

Net Life Years

0,164

Net QALYs

0,172

ICER

 

Cost per Life Year gained

USD 823,29

Cost per QALY gained

USD 786,08

Cost per Stroke Avoided (Ischemic and Hemorrhagic)

USD 5.422,01

Cost per Bleed Avoided (ICH including HS and Major Bleed)

USD 3.268,66